neoplasms

Exploring the potential of ginseng-derived compounds in treating cancer cachexia.

Cancer cachexia is a complex wasting syndrome characterized by significant loss of body weight and muscle mass in patients with advanced cancer. The disease is associated with increased systemic inflammation, altered neurohormonal signaling, and, in particular, an increased catabolic rate...

🗓️ 2025-11-21
📰 Publication: Journal Of Ginseng Research
Read MoreExploring the potential of ginseng-derived compounds in treating cancer cachexia.

Revisiting Cancer Cachexia Staging: Introducing an "At Risk" Category Based on AWGC Components.

Cancer cachexia is a multifactorial syndrome characterized by progressive weight loss, muscle wasting, and systemic inflammation. Early identification of individuals at risk for cachexia is essential for timely intervention, yet a universally accepted definition of the "at risk" stage remains...

🗓️ 2025-11-20
📰 Publication: Thoracic Cancer
Read MoreRevisiting Cancer Cachexia Staging: Introducing an "At Risk" Category Based on AWGC Components.

Pathways Contributing to Chemotherapy-Induced Myotoxicity Are Attenuated by EPA + DHA in a Clinically Relevant Model of Colorectal Cancer.

BACKGROUND

Skeletal muscle loss is a well-recognized consequence of cancer, and chemotherapy exacerbates myotoxicity through multiple mechanisms. Retaining muscle mass improves tumour response to therapies and tolerance to chemotherapy; hence, interventions to mitigate myotoxicity warrant investigations. This study aimed to investigate...

🗓️ 2025-11-17
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MorePathways Contributing to Chemotherapy-Induced Myotoxicity Are Attenuated by EPA + DHA in a Clinically Relevant Model of Colorectal Cancer.

Impaired cAMP-PKA-CREB1 signalling drives mitochondrial dysfunction in skeletal muscle during cancer cachexia.

Skeletal muscle wasting is a defining feature of cancer cachexia, a multifactorial syndrome that drastically compromises patient quality of life and treatment outcomes. Mitochondrial dysfunction is a major contributor to skeletal muscle wasting in cancer cachexia, yet the upstream molecular...

🗓️ 2025-11-13
Read MoreImpaired cAMP-PKA-CREB1 signalling drives mitochondrial dysfunction in skeletal muscle during cancer cachexia.

Primary-Stage Colon Cancer Impairs Muscle Energy Metabolism by Suppressing Mitochondrial Complex I Activity.

BACKGROUND

Colon cancer (CC), the third most common cancer worldwide, is accompanied by cachexia in 30% of patients. Its associated muscle loss directly impairs therapeutic response and survival. Early intervention is crucial, yet the underlying mechanisms of early-stage muscle dysfunction remain...

🗓️ 2025-11-12
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MorePrimary-Stage Colon Cancer Impairs Muscle Energy Metabolism by Suppressing Mitochondrial Complex I Activity.

Advancements of investigational agents for cancer cachexia: what clinical progress have we seen in the last 5 years?

INTRODUCTION

Cancer cachexia is a multifactorial syndrome affecting up to 80% of advanced cancer patients, associated with poor quality of life, increased cancer-treatment toxicity, and reduced survival. Despite its clinical burden, no FDA- or EMA-approved pharmacologic therapies currently exist.

AREAS COVERED

This review...

🗓️ 2025-11-12
📰 Publication: Expert Opinion On Investigational Drugs
Read MoreAdvancements of investigational agents for cancer cachexia: what clinical progress have we seen in the last 5 years?

A Creatinine-CAR Composite Index (CCAR) Optimized by Machine Learning for Prognosis in Cancer Cachexia.

BACKGROUND

Cancer cachexia is a multifactorial syndrome associated with poor prognosis and impaired quality of life in cancer patients. However, survival prediction in cancer cachexia remains difficult due to the lack of reliable biomarkers.

METHODS

This retrospective cohort study analysed data from 1,367...

🗓️ 2025-11-11
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreA Creatinine-CAR Composite Index (CCAR) Optimized by Machine Learning for Prognosis in Cancer Cachexia.

EyaHOST, a modular genetic system for investigation of intercellular and tumor-host interactions in Drosophila melanogaster.

Studying intercellular and interorgan interactions in animal models is key to understanding development, physiology, and disease. We introduce EyaHOST, a system for clonal combinatorial loss- and gain-of-function genetics in fluorescently labeled cells under QF2-QUAS eya promoter control. Distinct from mosaic...

🗓️ 2025-11-06
Read MoreEyaHOST, a modular genetic system for investigation of intercellular and tumor-host interactions in Drosophila melanogaster.

Changes in Lean Muscle Mass, Muscle Strength, and Physical Performance Following First-Line Chemotherapy in Patients With Lymphoma.

Lymphomas are common cancers affecting the lymphatic system. Chemotherapy is a standard treatment, yet its impact on patient's physical capacity remains understudied. This study aimed to evaluate changes in body composition, muscle strength, and physical performance in patients diagnosed with...

🗓️ 2025-11-04
📰 Publication: Hematological Oncology
Read MoreChanges in Lean Muscle Mass, Muscle Strength, and Physical Performance Following First-Line Chemotherapy in Patients With Lymphoma.

Efficacy and safety of anamorelin for cancer cachexia in patients with unresectable or recurrent gastric cancer: a multicentre, open-label, randomised controlled trial.

BACKGROUND

Anamorelin, a ghrelin receptor agonist, has shown efficacy in lung cancer cachexia. We conducted the first randomized controlled trial to evaluate its effects in gastric cancer cachexia.

METHODS

In this multicenter, open-label randomized controlled trial conducted across 10 hospitals in Japan, patients...

🗓️ 2025-11-03
📰 Publication: Eclinicalmedicine
Read MoreEfficacy and safety of anamorelin for cancer cachexia in patients with unresectable or recurrent gastric cancer: a multicentre, open-label, randomised controlled trial.

The mitochondrial-targeted antioxidant SkQ1 prevents skeletal muscle mitochondrial-apoptotic but not necroptotic signalling during ovarian cancer.

The degree to which mitochondrial-linked programmed cell death pathways contribute to skeletal muscle atrophy during cancer remains unknown. Here we combined a novel and robust mouse model of metastatic ovarian cancer with chronic administration of the mitochondrial-targeted antioxidant SkQ1 to...

🗓️ 2025-11-03
📰 Publication: Journal Of Physiology-London
Read MoreThe mitochondrial-targeted antioxidant SkQ1 prevents skeletal muscle mitochondrial-apoptotic but not necroptotic signalling during ovarian cancer.

Transcriptional landscape of skeletal muscle in cancer patients.

Bhatt et al. have identified two RNAome-based skeletal muscle subtypes in cancer cachexia. The first subtype is cachexia associated with weight and muscle loss, fiber atrophy, and shortened survival. Furthermore, this subtype has dysregulated post-transcriptional networks involving hub long noncoding...

🗓️ 2025-11-02
📰 Publication: Trends In Molecular Medicine
Read MoreTranscriptional landscape of skeletal muscle in cancer patients.

High Loss of Adipose Tissue During Neoadjuvant Chemotherapy Predicts Poor Prognosis in Patients With Gastric Cancer.

BACKGROUND

Gastric cancer (GC) patients often have nutritional risks or malnutrition, and neoadjuvant chemotherapy (NAC) tends to exacerbate malnutrition. Body composition parameters are associated with the prognosis of GC patients. Little is known about body composition changes during NAC and its...

🗓️ 2025-10-31
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreHigh Loss of Adipose Tissue During Neoadjuvant Chemotherapy Predicts Poor Prognosis in Patients With Gastric Cancer.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!